Jeff Sessions can't do it on his own. Trump has repeatedly said he would leave it to the states. this would leave the status unchanged, IMO. Of course, Trump could change his mind.

This doesn't apply to us, IMO, see list of securities

JPMorgan Chase Announces Completion and Final Results of its Cash Tender Offer for Certain Trust Preferred Securities

New York, November 7, 2016 - JPMorgan Chase & Co. ("JPMorgan Chase" or the “Firm”) announced today the completion and final results for its cash tender offer (the “Offer”) to purchase any and all of the trust preferred securities listed below. JPMorgan Chase has been advised that the aggregate liquidation amounts specified in the table below have been validly tendered and not validly withdrawn pursuant to the Offer.
CUSIP Number Issuer Title of Security Variable Distribution Rate Maturity of Underlying Debt Securities Aggregate Liquidation Amount Outstanding Aggregate Liquidation Amount Validly Tendered and Not Validly Withdrawn(1)
161480AA6 Chase Capital II Global Floating Rate Capital Securities, Series B 3 month LIBOR + 0.500% February 1, 2027 $485,150,000 $278,593,000
31945HAA3 First Chicago NBD Capital I Floating Rate Preferred Securities 3 month LIBOR + 0.550% February 1, 2027 $249,940,000 $157,908,000
161478AA0 Chase Capital III Floating Rate Capital Securities, Series C 3 month LIBOR + 0.550% March 1, 2027 $297,960,000 $221,937,000
16162LAA1 Chase Capital VI Floating Rate Capital Securities, Series F 3 month LIBOR + 0.625% August 1, 2028 $242,400,000 $179,120,000
46626YAA0 J.P. Morgan Chase Capital XIII Floating Rate Capital Securities, Series M 3 month LIBOR + 0.950% September 30, 2034 $467,650,000 $228,131,000
48123KAA4 JPMorgan Chase Capital XXI Floating Rate Capital Securities, Series U 3 month LIBOR + 0.950% February 2, 2037 $840,720,000 $515,870,000
48123UAA2 JPMorgan Chase Capital XXIII Floating Rate Capital Securities, Series W 3 month LIBOR + 1.000% May 15, 2047 $646,469,000 $50,582,000

(1) Includes $2,000,000 of Floating Rate Capital Securities, Series C and $2,640,000 of Floating Rate Capital Securities, Series U tendered by Notice of Guaranteed Delivery as to which tendered securities have yet to be delivered.

The $1,632,141,000 aggregate liquidation amount of trust preferred securities validly tendered and not validly withdrawn includes an aggregate of $4,640,000 liquidation amount of trust preferred securities tendered in accordance with guaranteed delivery procedures, which securities must be delivered by the close of business on November 8, 2016 as set forth in the Offer to Purchase referenced below.

The Offer expired at 5:00 p.m., New York City time, on November 4, 2016. JPMorgan Chase has accepted for payment all trust preferred securities validly tendered and not validly withdrawn pursuant to the Offer. Under the terms of the Offer, trust preferred securities validly tendered other than by notice of guaranteed delivery and not validly withdrawn will be paid for on the initial settlement date which is expected to be today, November 7, 2016. Under the terms of the Offer, trust preferred securities validly tendered by notice of guaranteed delivery and not validly withdrawn will be paid for on the final settlement date which is expected to be November 9, 2016.

The Offer was being made pursuant to an Offer to Purchase dated October 31, 2016 and the related Notice of Guaranteed Delivery.

J.P. Morgan Securities LLC acted as dealer manager for the Offer, and D.F. King & Co., Inc. is serving as the tender agent and information agent. Requests for documents may be directed to D.F. King & Co., Inc. by telephone at +1-212-269-5550 (banks and brokers) or +1-800-669-5550. Questions regarding the Offer may be directed to J.P. Morgan Securities LLC at +1-866-834-4666 or collect at +1-212-834-3424.

This press release is for informational purposes only and does not constitute an offer to purchase nor the solicitation of an offer to sell any securities. The Offer was made only pursuant to the Offer to Purchase and related Notice of Guaranteed Delivery and was not made to holders of trust preferred securities in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction.

JPMorgan Chase & Co. (NYSE: JPM) is a leading global financial services firm with assets of $2.5 trillion and operations worldwide. The Firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. A component of the Dow Jones Industrial Average, JPMorgan Chase & Co. serves millions of consumers in the United States and many of the world's most prominent corporate, institutional and government clients under its J.P. Morgan and Chase brands. Information about JPMorgan Chase & Co. is available at www.jpmorganchase.com.

Investor Contact:
Jason Scott, 212-270-7325

Media Contact:
Joseph Evangelisti, 212-270-7438
Related Links

Investor Relations
Quarterly Earnings
Annual Report & Proxy

http://www.tradecalls.org/2016/09/numina-capital-management-buys-14834507-stake-in-wmih-corporation-wmih-385379/

Looks like it happened in the last minute.

Invest $1 million and receive $149 million 20 years later? Isn't that what Bernie Madoff said? Just sayin'---it doesn't sound right to me.

That point was answered. The $600 million from the investors has not been spent to-date. When a deal is made the investors will invest additional funds to complete the deal. There will be leverage as well (debt).

He said the confidentiality agreement states that everything is confidential for 24 months. The who, the why and the amount, etc. This is common with these agreements. I was surprised that the time limit was only 24 months.

During the Q & A period, the speaker said the confidentiality agreement regarding the disclosure of our M & A target is for 24 months since last summer. They'll tell us next summer. I believe I heard him say that there should be a deal within 6 months. I was surprised that he pinned it down to such a short time frame.

Not correct, sorry. It's trade date. See link and IRS regs.

http://finance.zacks.com/stock-sale-reportable-based-trade-date-settlement-date-9690.html

You betcha!

If you have these in your escrow account, of course you are entitled to escrow money. Otherwise, you wouldn't have them.

Using reverse splits to force out minority shareholders.

This explains the reverse split process (a Washington State court decision). I've been concerned that forcing out the minority shareholders could be the motive for a reverse split in WMIH stock, if this is actually in the works. Up to now, this seems to be board speculation. (The Washington State decision supports the company's right to do this). WMIH is now a Delaware corporation, and Delaware is VERY corporation friendly.

http://companycounsel.net/2010/09/28/reverse-stock-splits-can-be-used-to-force-out-minority-shareholders-says-washington-supreme-court/

Dick Fuld

I'm getting really tired of reading snide posts about some of our members who make snide or negative posts. Just press the IGNORE button. I did.

A surge with HIGH volume would really please me. This volume is nothing.

These accounts belonged to depositors who were told to bank elsewhere.

The $350 billion belonged to the depositors.

Good luck nurse, and stay safe!

How big is their office? They may not be expecting a crowd. LOL

Couldn't you sell the shares to get your cash? We won't get a choice.

Also $3,000 for single. $1,500 for married filing separately.

I agree investorhub123. I've converted stocks to my Roth multiple times in the last few years. It takes seconds online. I just indicated the stocks that I wanted converted (into my existing Roth) and that was that.

Use it, or lose it.

http://www.snopes.com/medical/disease/ebolaairborne.asp

False per Snopes.

Here's why.

http://online.wsj.com/articles/SB10001424052748703712504576237070211101688

Elizabeth Warren demands jail time for bankers.

http://investorshub.advfn.com/boards/read_msgs.aspx?board_id=11133&NextStart=404523&BatchSize=50

No, they're dead. They are SOL. They would have to sue on their own nickles.

No releases, no distribution to them, period.

Everyone, I think they're just planning on investing idle funds until it's time to make distributions. They would invest it in cash equivalents such as a money market fund. This is not the same as a long-term investment, just good money management.

removed by poster. question answered.

Maybe they needed the profits for the coffee fund.

Those were forms W-4, not W-2.

You didn't put yourself on Ignore, did you?

GW Pharma, Insys Face Off In Cannabis Drug Space

By AMY REEVES, INVESTOR'S BUSINESS DAILY
Posted 08/08/2014 04:45 PM ET



Over the past 18 years, 23 U.S. states have legalized marijuana for medical uses, leading in the past few years to a rush of startups popping up like, well, weeds to cater to this new market.

In June, New York became the latest state to OK medical marijuana.

While many observers mention GW Pharmaceuticals (NASDAQ:GWPH) as one of the "pot stocks," company CEO Justin Gover disagrees with that characterization.
GW's drug development focuses on cannabinoids, or substances derived from cannabis, such as THC and CBD.

GW's drug development focuses on cannabinoids, or substances derived from cannabis, such as THC and CBD. View Enlarged Image

"We started out 16 years ago with a very clear objective in mind," Gover told IBD. "It was really about what we felt was an overlooked source of medicines in the form of the cannabis plant. But not with a view of looking at it as anything other than as a source of bona fide prescription medicines that would go through an FDA process."

The difference is apparent in the stock itself. While there are scores of medical-marijuana stocks trading over the counter — often for pennies — GW debuted on the Nasdaq in June 2013. From its IPO price of 8.90, GW stock has soared to near 82. Shares peaked at 111 on July 1.

GW is still unique on the stock market in being focused on cannabinoids — that is, substances derived from cannabis. But the very day that it first traded on the Nasdaq also brought the debut of Insys Therapeutics (NASDAQ:INSY). Insys focuses on pain medicines but is also working on a cannabinoid, which likely will bring it into direct competition with GW.

(The only other marijuana drug-related stock traded on major U.S. markets is AbbVie (NYSE:ABBV), which sells Marinol, a drug based on the THC chemical compound in a cannabis plant and designed to give AIDS sufferers their appetites back.)

No Psychoactive Effects

The GW and Insys substance in question is cannabidiol, a cannabinoid that appears in high concentrations in the cannabis plant but has no psychoactive effects. GW is testing it under the brand name Epidiolex to treat two forms of severe childhood epilepsy, Dravet syndrome and Lennox-Gastault syndrome.

Both types constitute only a fraction of epilepsy cases. Morgan Stanley analyst David Friedman estimates there are only about 5,000 Dravet cases in the U.S., and 15,000 Lennox-Gastault cases. But these patients respond poorly to current epilepsy treatments.

That combination of small patient size, severity of the condition and lack of existing treatments led the FDA in February to designate Epidiolex an "orphan drug." That means that, if approved, the product will be granted seven years of market exclusivity, which will potentially allow GW to set the price lucratively high. Such a strategy has paid off for Alexion Pharmaceuticals (NASDAQ:ALXN) and Vertex Pharmaceuticals (NASDAQ:VRTX), and many other firms hope for the same such success.

Will Market Drug Itself

Friedman estimates peak annual sales of Epidiolex could hit 800 million British pounds, or about $1.4 billion at current exchange rates. And if all goes according to plan, GW will get all of it. Gover says the company is using the money raised by its U.S. IPO partly to build the capacity to market the drug itself, rather than license it out.

Insys, however, hopes to spoil those ambitions. The company has developed its own cannabidiol which, unlike GW's plant-based product, is wholly synthetic. Last month, the FDA also granted orphan-drug status to Insys' product for Dravet and Lennox-Gastault, potentially setting up a head-on collision.
GW's Sativex, an oral spray that's in part a formulated extract of the cannabis sativa plant, is sold in Europe to treat spasticity related to MS.

GW's Sativex, an oral spray that's in part a formulated extract of the cannabis sativa plant, is sold in Europe to treat spasticity related to MS. View Enlarged Image

"You can get orphan status applied to different investigational drugs that are targeting the same indication," said Lala Gregorek, an analyst with Edison Investment Research who covers GW but not Insys. "But it's quite often the case that the one that gets to market first is the one that blocks the entry of the second. ... Insys is behind GW with respect to (clinical trials)."

When asked about this, Insys CEO Michael Babich emphasized that his company has options.

"With Lennox-Gastault and Dravet, I believe it's a race," he acknowledged. "Insys, in particular, works toward other indications in cannabidiol as well. That wouldn't prohibit us from getting approval in a different indication."

Babich says Insys is investigating uses for adult epilepsy, cancer-related pain, glioblastoma (a type of brain tumor) and addiction to heroin and other opiates.

GW, too, is investigating the cancer-pain indication for its older product, Sativex, a different kind of cannabinoid that is sold in Europe as a treatment for spasticity related to multiple sclerosis. It also has other cannabinoids in testing for brain tumors, diabetes, ulcerative colitis, schizophrenia and an orphan indication called neonatal hypoxic-ischemic encephalopathy.

All these treatments, however, are still far in the future. Friedman expects Epidiolex to launch in the U.S. in 2017, with blockbuster sales not arriving until the 2020s. Despite the revenue from Sativex, GW expects to keep operating at a loss for the rest of the decade.

With so much testing to do, unknown risks could still develop. But Friedman draws assurance of cannabidiol's safety from, of all things, its long history as a recreational drug.

"One other aspect to GW's cannabis platform is the large, albeit quite 'informal' safety database for cannabis," he wrote in his April 22 coverage-initiation report. "Given the wide consumption globally of cannabis, we believe that a major medical issue with its use would be well known."

Read More At Investor's Business Daily: http://news.investors.com/technology/080814-712488-gwph-insy-race-with-competing-epilepsy-drugs.htm#ixzz3AfQpwZEw

Refreshing, isn't it?

Renew it with USPS for extra insurance.

That's why I SPECIFICALLY said "capital gains". Only capital GAINS are taxable. Capital losses on PERSONAL ASSETS are not deductible. You are correct that you can't claim a capital loss on that piece of poop you just sold. LOL.

(Simply said: capital gains are the difference between the selling price and the purchase price, for example, selling price of $50,000 less cost of $10,000 is $40,000 capital gain).

Thank you Olti!

Ha ha ha ha. And you sound SO SURE!!!

Wrong. Capital gains taxes apply to gains on cars and autos.